ImmunityBio, Inc.
IBRX
$2.51
$0.041.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5,084.17% | 7,160.98% | 2,314.63% | -88.89% | 90.41% |
| Total Other Revenue | 148.92% | 85.37% | 39.02% | -- | -- |
| Total Revenue | 5,333.09% | 7,346.34% | 2,453.66% | -88.89% | 90.41% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5,333.09% | 7,346.34% | 2,453.66% | -88.89% | 90.41% |
| SG&A Expenses | 25.13% | 11.47% | 49.63% | 25.85% | 21.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.08% | 7.66% | 17.84% | -14.92% | 0.35% |
| Operating Income | 17.87% | -0.15% | -16.66% | 14.68% | -0.28% |
| Income Before Tax | 74.65% | 10.34% | 2.63% | -15.05% | -115.58% |
| Income Tax Expenses | -- | -- | -- | -- | -217.65% |
| Earnings from Continuing Operations | 74.65% | 10.34% | 2.63% | -15.05% | -115.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -22.73% | -61.67% | -94.01% | -91.25% | -80.18% |
| Net Income | 74.65% | 10.31% | 2.40% | -15.27% | -115.67% |
| EBIT | 17.87% | -0.15% | -16.66% | 14.68% | -0.28% |
| EBITDA | 18.36% | -0.33% | -17.98% | 15.21% | -1.13% |
| EPS Basic | 76.85% | 35.77% | 37.85% | 26.62% | -30.03% |
| Normalized Basic EPS | 76.86% | 35.73% | 37.74% | 26.49% | -38.92% |
| EPS Diluted | 73.37% | 25.13% | 37.50% | 26.62% | -30.70% |
| Normalized Diluted EPS | 76.90% | 35.89% | 37.74% | 26.49% | -38.92% |
| Average Basic Shares Outstanding | 9.51% | 39.63% | 57.03% | 57.06% | 65.88% |
| Average Diluted Shares Outstanding | 9.70% | 40.05% | 57.03% | 57.06% | 65.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |